跳至主要内容
临床试验/NCT04917757
NCT04917757进行中(未招募)不适用

Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry

Wuerzburg University Hospital2 个研究点 分布在 2 个国家目标入组 3,656 人开始时间: 2015年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
3,656
试验地点
2
主要终点
Mortality

研究概览

简要总结

The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.

详细描述

The NAPACA Outcome Study is part of the ENSAT Registry (https://registry.ensat.org/)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age ≥18 years
  • adrenal incidentaloma (≥ 1cm) detected by cross-sectional imaging between January 1, 1996 and December 31, 2015
  • imaging characteristics suggestive for an adrenal adenoma or excluded malignancy by follow-up imaging
  • availability of a 1 mg dexamethasone test result
  • follow-up data on living status and occurrence of cardiovascular events
  • follow-up duration of at least 36 months.

排除标准

  • proven pheochromocytoma, primary hyperaldosteronism or adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome
  • clinical features suggestive for overt Cushing's syndrome; urinary free cortisol (UFC) ≥ 2-fold higher than the upper limit of normal of the local assay
  • any active malignancy (including adrenocortical cancer) at the time of primary diagnosis

结局指标

主要结局

Mortality

时间窗: From date of primary diagnosis of the adrenal incidentaloma to the date of death or last follow-up (data lock August 31, 2019). Median follow-up duration was 7.0 years.

death

次要结局

  • Cardiovascular Morbidity(From date of primary diagnosis of the adrenal incidentaloma to the date of the first CV event or death or last follow-up (data lock August 31, 2019). Median follow-up duration was 7.0 years.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Martin Fassnacht

Chair Dept. of Endocrinology and Diabetes

Wuerzburg University Hospital

研究点 (2)

Loading locations...

相似试验